FDA Set To Strengthen Inspections Of Chinese Drugmakers In Aftermath Of Heparin Deaths – CDER Official
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER's Buhay notes "there will be many multiples" of the current number of inspections following the opening of three new offices in China.